

RESEARCH ARTICLE

High prevalence and diversity of extended-spectrum β -lactamase and emergence of OXA-48 producing *Enterobacterales* in wildlife in CataloniaLaila Darwich^{1,2*}, Anna Vidal¹, Chiara Seminati¹, Andreu Albamonte¹, Alba Casado¹, Ferrán López¹, Rafael A. Molina-López³, Lourdes Migura-García²

1 Departament de Sanitat i Anatomia Animal, Universitat Autònoma de Barcelona (UAB), Cerdanyola del Vallès, Spain, **2** IRTA, Centre de Recerca en Sanitat Animal (CRESA, IRTA-UAB), Campus de la Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain, **3** Catalan Wildlife Service, Centre de Fauna Salvatge de Torreferrussa, Santa Perpètua de Mogoda, Barcelona, Spain

* laila.darwich@uab.cat OPEN ACCESS

Citation: Darwich L, Vidal A, Seminati C, Albamonte A, Casado A, López F, et al. (2019) High prevalence and diversity of extended-spectrum β -lactamase and emergence of OXA-48 producing *Enterobacterales* in wildlife in Catalonia. PLoS ONE 14(8): e0210686. <https://doi.org/10.1371/journal.pone.0210686>

Editor: Monica Cartelle Gestal, University of Georgia, UNITED STATES

Received: December 28, 2018

Accepted: July 2, 2019

Published: August 5, 2019

Copyright: © 2019 Darwich et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting Information files.

Funding: The contract of LMG was supported by the Instituto Nacional de Investigación y Tecnología Agraria y Alimentaria (INIA) and the European Social Fund. AV was supported by a PIF grant from the Universitat Autònoma de Barcelona. The funders had no role in study design, data collection

Abstract

Most of the studies focused on antimicrobial resistance (AMR) performed in wildlife describe *Escherichia coli* as the principal indicator of the selective pressure. In the present study, several species of *Enterobacterales* with a large panel of cephalosporin resistant (CR) genes have been isolated from wildlife in Catalonia. A total of 307 wild animals were examined to determine the prevalence of CR enterobacteria, AMR phenotypes and the presence of common carbapenem and CR genes. The overall prevalence of CR-phenotype was 13% (40/307): 17.3% in wild mammals (18/104) and 11.5% in wild birds (22/191) ($p < 0.01$). Hedgehogs showed the highest prevalence (13.5% of 104) of the mammal specimens, and raptors the highest in bird specimen (7.3% of 191). Although CR *E. coli* was the most frequently isolated (45%), other CR- *Enterobacterales* like *Klebsiella pneumoniae* (20%), *Citrobacter freundii* (15%), *Enterobacter cloacae* (5%), *Proteus mirabilis* (5%), *Providencia* spp (5%) and *Serratia marcescens* (2.5%) were also isolated. A high diversity of CR genes was identified among the isolates, with 50% yielding *bla*CMY-2, 23% *bla*SHV-12, 20% *bla*CMY-1 and 18% *bla*CTX-M-15. Additionally, resistance to carbapenems associated to OXA-48 gene was found. Most of the CR isolates, principally *K. pneumoniae* and *C. freundii*, were multi-resistant with co-resistance to fluoroquinolones, tetracycline, sulphonamides and aminoglycosides. This study reports high prevalence of *Enterobacterales* harbouring a variety of CR genes and OXA-48 mediated-carbapenem resistance, all of them frequently associated to nosocomial human infections, for the first time in wild mammals and wild birds. Implementation of control measures to reduce the impact of anthropogenic pressure in the environment is urgently needed.

and analysis, decision to publish, or preparation of the manuscript.

Competing interests: The authors have declared that no competing interests exist.

Introduction

In the last decades, the prevalence of opportunistic and antimicrobial resistant (AMR) bacteria associated with nosocomial infections has increased in hospital settings. The overuse of antibiotics in human and veterinary medicine have led to the spread of AMR pathogens, becoming a global health problem [1].

Extended-spectrum β -lactamases (ESBLs) and AmpC-type β -lactamases (AmpC) are the most common enzymes that confer resistance to broad-spectrum cephalosporins among members of the family *Enterobacterales*. These β -lactamases have extensively diversified in response to the clinical use of new generation drugs: cephalosporins, carbapenems and monobactams [2]. There are currently two classification systems for beta-lactamase enzymes. The first one classifies beta-lactamases according to the amino acid sequence [3,4]. The second classification, described by Bush and Jacoby (2010) is based on the functional activity of the enzymes. Within this classification, the group 1 contains cephalosporinases encoded in the chromosome of many *Enterobacterales*, such as AmpC, CMY, ACT, FOX and MIR. Some variants of these enzymes have also been detected in plasmids. The group 2 serine beta-lactamase represents the largest group with a broad spectrum against penicillins, cephalosporins, and carbapenems. They include the TEM, SHV, CTX, OXA and KPC enzymes. These enzymes are mostly encoded by genes located in plasmids that can be horizontally transferred to different bacteria genera [1]. Finally, the group 3 metallo-beta-lactamases (MBLs) are zinc dependent and include NDM, IMP, VIM and SPM enzymes [5].

Carbapenems are last-line beta-lactam antibiotics with the broadest spectrum of activity. Nowadays, carbapenems are commonly used in hospital settings for the treatment of life-threatening infections caused by *Enterobacterales* resistant to beta-lactamic drugs, including cephalosporins, monobactams and inhibitors of beta-lactamases. However, the emergence of resistance to carbapenems mediated by the production of carbapenemases has led to limited therapeutic options in human health [6]. The OXA-48 variant of carbapenemases is becoming highly prevalent in human clinical infections [7].

The dissemination of cephalosporin resistance (CR) has been studied widely in *Enterobacterales* from humans and livestock, whereas studies concerning the environment, including wildlife, are still lacking [2]. In recent years, an important increase of CR *Escherichia coli* has been reported in different epidemiological settings such as humans, pets, livestock, retail meat and the environment [8–13]. The study of wildlife as sentinel of the AMR environmental contamination has recently acquired more consideration worldwide [14]. However, most of the environmental-wildlife interface studies have been focused on wild birds, as principal AMR disseminators by their migratory routes, with a limited variety of AMR bacteria species described. Isolation of CR-carrying bacteria from wild birds has been globally reported in *E. coli* [15–20] and less frequently in *Klebsiella pneumoniae* [21]. All these results confirm the dissemination success of ESBL bla_{SHV-12} and bla_{CTX-M} variants in wild birds worldwide. More recently, presence of CR *E. coli* has also been described in wild mammals, but at lower prevalence in comparison with wild birds [22].

In the present study, we report for the first time in Spain, the presence of diverse families of CR-encoding genes in a large variety of *Enterobacterales* including *E. coli*, *K. pneumoniae*, *Citrobacter freundii*, *Enterobacter cloacae*, *Serratia marcescens* and *Proteus mirabilis* in wild mammals and wild birds. Furthermore, we describe the presence of carbapenemase resistant *E. coli* and *P. mirabilis* associated with the presence of OXA-48 variant in isolates of wildlife origin. These bacteria are frequently found in recurrent and severe urinary tract infections and other nosocomial infections in hospitals of Spain [7,23].

Material and methods

Study population

Wild animals attended at the Wildlife Rehabilitation Centre (WRC) of Torreferrusa (Catalonia, North-East Iberian Peninsula) were analysed between November 2016 and May 2017. This is a public WRC under the direction of the Catalan Wildlife-Service (“Direcció General de Polítiques Ambientals, Departament de Territori i Sostenibilitat of the Generalitat de Catalunya”). Sampling methods and handling protocols of animals were in agreement with the Catalan Wildlife Service who stipulates the management protocols and Ethical Principles according to the Spanish legislation [24]. All animals were examined and tested using cloacal or rectal swabs on arrival at the centre before receiving any pharmacologic or antimicrobial treatment. The most frequent cause of hospitalization was related to anthropogenic origin due to direct persecution (gunshot, poisoning, illegal captivity or traps) to involuntary human induced threats (collisions with vehicles, fences or electric lines and electrocution).

Microbiological analysis

Rectal and cloacal swabs were plated in MacConkey agar supplemented with ceftriaxone (1mg/L). Single colonies growing on the plate were subculture and identified biochemically using API (bioMérieux, Marcy l’Etoile, France) or VITEK 2 (bioMérieux, Spain) systems.

Antimicrobial susceptibility testing

Minimal inhibitory concentration (MIC) was performed using a commercial broth microdilution method (VetMIC GN-mo, SVA, Sweden) for the following antimicrobials: ampicillin (1 to 128 mg/liter), cefotaxime (0.016 to 2 mg/liter), ceftazidime (0.25 to 16 mg/liter), nalidixic acid (1 to 128 mg/liter), ciprofloxacin (0.008 to 1 mg/liter), gentamicin (0.12 to 16 mg/liter), streptomycin (2 to 256 mg/liter), kanamycin (8 to 16 mg/liter), chloramphenicol (2 to 64 mg/liter), florfenicol (4 to 32 mg/liter), trimethoprim (1 to 128 mg/liter), sulfamethoxazole (8 to 1,024 mg/liter), tetracycline (1 to 128 mg/liter), and colistin (0.5 to 4 mg/liter). The *E. coli* ATCC 25922 was used as control strain. Epidemiological cut-off values (ECOFF) selected were those described by the European Committee on Antimicrobial Susceptibility testing (EUCAST, <https://mic.eucast.org/Eucast2/>). For the combinations of species-antimicrobial with no cut-off values defined by EUCAST, ECOFF values were obtained from the British Society for Antimicrobial Chemotherapy (BSAC) or the Clinical and Laboratory Standards Institute (CLSI, 2017).

Molecular characterization of antimicrobial resistance genes

The detection of genes coding for ESBLs *-bla*_{CTX-M} [25], *bla*_{TEM} [26], *bla*_{SHV} [27]-, AmpCs *-bla*_{CMY-1} [28], *bla*_{CMY-2} [29], carbapenemases *-bla*_{OXA-48}, *bla*_{VIM}, *bla*_{IMP}, *bla*_{NDM} and *bla*_{KPC} [30]- and colistin-resistance genes *mcr1-5* variants [31] was carried out using PCR as previously described (S1 Table).

Sanger DNA sequencing was done for *bla*_{TEM}, *bla*_{SHV}, *bla*_{CTX-M}, and *bla*_{OXA} PCR products at the Genomic and Bioinformatics Service of the Universitat Autònoma de Barcelona (Spain). Sequences and chromatograms were manually explored to trim bad-quality bases with BioEdit 7.2. Once the assembly of the consensus sequences was done, partial sequences were aligned using Clustal Omega program, and finally blasted against the public database (National Center for Biotechnology Information, NCBI). Allelic variants of the ESBL-resistance genes were determined based on these partial sequences, and AmpC genes were classified according to the CMY-1 and CMY-2 groups.

Statistical analysis. Descriptive analysis was performed under 95% confidence, using SPSS Advanced Models TM 15.0 (SPSS Inc. 233 South Wacker Drive, 11th Floor Chicago, IL 60.606–6412). The Chi-square test or Fisher exact test was used for comparison between proportions when appropriate. Statistically significant results were considered for unadjusted p -value < 0.05 .

Results

The sample size comprised 307 wild animals belonging to 67 different species grouped as birds (62%), mammals (34%) and reptiles (4%) (Fig 1). Animals came from different regions of Catalonia with a high density of urban areas and pig farming production.

Ceftriaxone resistant isolates were detected in 65 out of the 307 (21%) faecal samples analysed. Of those, 40 harboured ESBL or AmpC-encoding genes, representing an overall prevalence of 13% (Fig 2). The prevalence of CR-carrying isolates was 17.3% in wild mammals (18/104) and 11.5% in wild birds (22/191). Within the mammal group, hedgehogs showed the largest prevalence of resistant isolates in comparison to the total mammal species examined (13.5%, 14/104, $p = 0.022$). Precisely, 67% of the Algerian (2/3) and 26% of the European (12/47) samples





Fig 1. Proportion of wildlife analysed in the study according to the zoological category. Animal groups: raptors (different species of birds of prey and owls), wild birds (principally passerines and seagulls), insectivorous (European and Algerian hedgehogs), carnivores (mainly mustelids), and other mammals (wild boars and roe deer).

<https://doi.org/10.1371/journal.pone.0210686.g001>

Prevalence of MDR bacteria




Fig 2. Prevalence of cephalosporin resistant (CR) bacteria in the different wildlife categories.

<https://doi.org/10.1371/journal.pone.0210686.g002>

harboured CR-genes. Within the bird group, raptors represented the highest prevalence with 7.3% (14/191) of the total bird specimens [23% (14/60) of the raptor species examined] (Fig 2).

CR isolates belonged to several genera within the Enterobacterales order, with *E. coli* being detected most frequently (45%). Interestingly, other clinically relevant enterobacteria, including *K. pneumoniae* (20%), *C. freundii* (15%), *E. cloacae* (5%), *P. mirabilis* (5%), *Providencia* spp (5%) and *S. marcescens* (2.5%) were also identified as carriers of CR genes. The proportion of positive samples for AmpC-encoding genes was 65% (26/40) distributed in 27% *bla*_{CMY-1} and 38% *bla*_{CMY-2} families. Additionally, 65% (26/40) of the isolates exhibited ESBL genes with *bla*_{SHV-12} (9/40, 22.5%) and *bla*_{CTX-M-15} (6/40, 15%) representing 35% and 23% of the total ESBL respectively. Isolates from 12 animals presented the combination of both, ESBL and

AmpC genes. Finally, mammals and raptors shared the largest part of the detected ESBL types, and other minority gene variants, such as *bla*_{CTX-M-3} and *bla*_{SHV-11} or *bla*_{SHV-167} were only detected in mammals or raptors, respectively (Fig 3).

A high genetic diversity of CR encoding genes was observed in all *Enterobacterales*, with 40% (16/40) of the isolates harbouring 2 to 5 different resistance genes in the same isolate (Table 1). Furthermore, the carbapenemase-encoding gene OXA-48 was detected in *E. coli* and *P. mirabilis* isolated from European hedgehog and Barn owl, respectively (Table 1). Other carbapenemase-encoding genes tested were not found.

Most of the ESBL/AmpC *Enterobacterales* isolated (92%), with the exception of *E. cloacae*, were multiresistant with a common resistance phenotype comprising β -lactams-quinolones-tetracycline-sulfamethoxazole/trimethoprim (Table 1). *K. pneumoniae* and *C. freundii* isolates both presented a multi-drug resistance profile including the resistance to aminoglycosides (Table 2). Moreover, 90% of the *K. pneumoniae* isolates were resistant to ciprofloxacin and




Fig 3. Venn diagram showing the distribution of AMR genes in the different animal groups encountered in this study.

<https://doi.org/10.1371/journal.pone.0210686.g003>

Table 1. Prevalence and antimicrobial resistance genotypes and phenotypes of beta-lactamase producing *Enterobacterales* detected in wildlife.

Scientific name (common name)	Total sample	AMR genes		Bacterial spp	Drug-resistance genes	Resistance phenotype to non-Beta-lactams
		n	Prev			
Mammals (N = 104)	N	n	Prev			
<i>Aetechnus algirus</i> (Algerian hedgehog)	3	2	67%	<i>Escherichia coli</i>	CMY-2	CIP, NAL, KAN, TMP
				<i>Klebsiella oxytoca</i>	CTX-M-3	GEN, ST, FF, CF, TET, COL, TMP
<i>Erinaceus europaeus</i> (European hedgehog)	47	12	26%	<i>Escherichia coli</i>	CMY-2	nd
				<i>Escherichia coli</i>	CMY-2	KAN
				<i>Escherichia coli</i>	CMY-2	nd
				<i>Escherichia coli</i>	SHV-12	STR
				<i>Escherichia coli</i>	SHV-11,OXA-48	CIP, NAL, KAN, TET, SUL, TMP
				<i>Klebsiella pneumoniae</i>	CMY-1,CMY-2, SHV-1,TEM-1, CTX-M-15	CIP, GEN, ST, KAN, TET, SUL, TMP
				<i>Klebsiella pneumoniae</i>	SHV-11, TEM-1	CIP, NAL, GEN, STP, KAN, TET, SUL, TMP
				<i>Klebsiella pneumoniae</i>	SHV-28	CIP, NAL, GEN, STR, KAN, TET, COL, SUL, TMP
				<i>Klebsiella pneumoniae</i>	SHV-12	CIP, NAL, KAN, TET, SUL, TMP
				<i>Citrobacter freundii</i>	CMY-2, TEM-1	CIP, NAL, KAN, TET, TMP
<i>Capreolus capreolus</i> (European roe deer)	2	1	na	<i>Citrobacter freundii</i>	CMY-2, SHV-12	CIP, NAL, GEN, TET, SUL, TMP
				<i>Enterobacter cloacae</i>	CMY-2	SUL
				<i>Meles meles</i> (European badger)	1	1
<i>Mustela vison</i> (American mink)	13	1	8%	<i>Enterobacter cloacae</i>	CMY-2	SUL
PREVALENCE IN MAMMALS	104	18	17.3%			
Raptors (n = 108)	N	n	Prev			
<i>Accipiter gentilis</i> (northern goshawk)	13	3	23%	<i>Escherichia coli</i>	TEM-1	COL
				<i>Escherichia coli</i>	CMY-2	CIP, NAL
				<i>Proteus mirabilis</i>	CMY-1, CMY-2, SHV-28, TEM-1	CIP, NAL, GEN, STR, KAN, TET, SUL, TMP
<i>Accipiter nisus</i> (Eurasian sparrowhawk)	8	3	38%	<i>Escherichia coli</i>	CMY-1, SHV-1, TEM-1, CTX-M-15	CIP, NAL, KAN, TET, SUL, TMP
				<i>Escherichia coli</i>	TEM-1	CIP, TET, TMP
				<i>Serratia marcescens</i>	CMY-1, CTX-M-15	CIP, TET, COL, SUL, TMP
<i>Bubo bubo</i> (Eurasian eagle-owl)	1	1	na	<i>Escherichia coli</i>	CMY-1, SHV-167	nd
<i>Buteo buteo</i> (Common buzzard)	17	2	12%	<i>Escherichia coli</i>	SHV-12	ST, CHL, TET, SUL, TMP
				<i>Providencia alcalifaciens</i>	SHV-12	CIP, NAL,GEN,ST,KAN, FF,CHL, TET, SUL, TMP
<i>Strix aluco</i> (Tawny owl)	18	3	17%	<i>Klebsiella pneumoniae</i>	CMY-2, SHV-28	STR, SUL, TMP
				<i>Escherichia coli</i>	CMY-2, SHV-1	nd
				<i>Klebsiella pneumoniae</i>	SHV-12, CTX-M15	CIP
<i>Tyto alba</i> (Barn owl)	3	2	67%	<i>Escherichia coli</i>	CMY-2	CIP, NAL, STR, TET
				<i>Proteus mirabilis</i>	SHV-12,TEM-1, OXA-48	CIP, NAL, STR, KAN, CF, TET, COL, SUL,TMP
Other birds (n = 83)	N	n	Prev			

(Continued)

Table 1. (Continued)

Scientific name (common name)	Total sample	AMR genes		Bacterial spp	Drug-resistance genes	Resistance phenotype to non-Beta-lactams
<i>Carduelis carduelis</i> (European goldfinch)	12	1	8%	<i>Citrobacter freundii</i>	CMY-2	CIP, NAL, GEN, STR, KAN, CHL, TET, SUL, TMP
<i>Carduelis choris</i> (European Greenfinch)	2	1	na	<i>Klebsiella pneumoniae</i>	CMY-1	CIP, NAL, KAN, FF, CHL, SUL
<i>Larus michahellis</i> (Yellow-legged gull)	7	1	14%	<i>Escherichia coli</i>	CTX-M-15	CIP, NAL, GEN, KAN, TET, SUL, TMP
<i>Serinus serinus</i> (European serin)	6	1	17%	<i>Klebsiella pneumoniae</i>	CMY-1, SHV-28	CIP, NAL, STR, KAN, TET, SUL, TMP
<i>Streptopelia decaocto</i> (Eur. collared dove)	1	1	na	<i>Citrobacter freundii</i>	CMY-2	FF, TMP
<i>Sylvia melanocephala</i> (Sardinian warbler)	6	2	33%	<i>Escherichia coli</i>	CMY-2	CIP, NAL
				<i>Providencia spp</i>	CTX-M-15, CMY-1	CIP, NAL, GEN, STR, KAN, CHL, TET, SUL, TMP
<i>Turdus merula</i> (Common blackbird)	8	1	13%	<i>Escherichia coli</i>	CMY-2	CIP, NAL, KAN, TMP
PREVALENCE IN BIRDS	191	22	11.5%			

CIP, Ciprofloxacin; NAL, Nalidixic acid; GEN, Gentamicin; STR, Streptomycin; KAN, Kanamycin; FF, Florfenicol; CHL, Chloramphenicol; TET, Tetracycline; COL, Colistin; SUL, Sulphamethoxazole; TMP, Trimethoprim. nd, not detected.

<https://doi.org/10.1371/journal.pone.0210686.t001>

sulphamethoxazole, 70% to kanamycin, 55% to streptomycin, and 10% to florfenicol. Additionally, 83% of the tested *C. freundii* isolates exhibited resistance to trimethoprim and nalidixic acid and 67% to tetracycline (Table 2). Although none of the *mcr*-genes were detected in this study, the colistin resistant phenotype was observed in *Klebsiella* spp isolated from a European greenfinch and Algerian hedgehog, and in a *Providencia* spp isolated from a common buzzard.

Discussion

This study identifies for the first time a high percentage of wild mammals and wild birds as carriers of potential nosocomial *Enterobacterales* harbouring diverse ESBL, CMY and OXA-48 genes. Moreover, most of the isolates principally *K. pneumoniae* and *C. freundii*, presented a high prevalence of resistance also to fluoroquinolones.

In general, *E. coli* is the most reported ESBL/pAmpC-producing enterobacteria worldwide, with increasing frequency from animals, food, environmental sources and humans. In recent years, CR- *E. coli* transmission has been reported in different hosts, demonstrating a close human-animal ESBL/pAmpC gene similarity between livestock (broilers and pigs) and personnel working at the farms [13]. Additionally, similar CR genes have been reported between isolates from the community and those from human clinical settings, sewage water and wild birds [13].

Although ESBL transmission has been studied extensively in *Enterobacterales* from humans and livestock, data on antimicrobial resistance in the environment is still limited [2]. Moreover, most of the studies related to ESBL-carrying bacteria in wildlife are focused on the wild bird population and mainly restricted to *E. coli* species [32]. Several studies conducted in *E. coli* from avian species have identified *bla*_{CTX-M-1}, *bla*_{CTX-M-14}, *bla*_{CTX-M-15} and *bla*_{SHV-12} as the predominant ESBL types circulating in Spain [15, 33–36], Portugal [37], Tunisia [20], The Netherlands [38], Poland [39] and the Czech Republic [40]. Contrarily, in the present study, *bla*_{CTX-M-1} and *bla*_{CTX-M-14} were not detected in our avian species, but *bla*_{SHV-12} and *bla*_{CTX-M-15} were the most

Table 2. Minimal inhibitory concentration of *E. coli*, *K. pneumoniae* and *C. freundii* isolates of wildlife origin. Dilution ranges for each antimicrobial are those contained within the white area. Vertical lines indicate epidemiological cut off values (ECOFF) or clinical breakpoints in those cases where ECOFF values have not been described.

<i>E. coli</i> (n = 18)															
MIC [$\mu\text{g/mL}$]:	0.12	0.25	0.5	1	>2	4	8	16	>16	32	64	>128	256	>512	R (%)
Ampicilin											3	15			100
Cefotaxime	1	1	1	2	12	1									89
Ceftazidime				2		1	1	7	7						100
Ciprofloxacin	6	2	2	8											67
Nalidixic acid					2	3	4					9			50
Gentamicin			9	8						1					5.5
Streptomycin						7	3	5		2	1				17
Kanamycin							12	2	4						33
Florfenicol						4	12	2							0
Chloramphenicol					2	8	5	1		2					11
Tetracycline				6	6					1	2	3			33
Colistin			17			1									5.5
Sulphamethoxazole							2	9		1	1			5	28
Trimethoprim	1	7	2							8					44
<i>K. pneumoniae</i> (n = 9)															
MIC [$\mu\text{g/mL}$]:	0.12	0.25	0.5	1	>2	4	8	16	>16	32	64	>128	256	>512	R (%)
Ampicilin ^a											1	8			100
Cefotaxime					9										100
Ceftazidime							3		6						100
Ciprofloxacin		1		8											100
Nalidixic acid ^a						1			2	1		5			88
Gentamicin		1	5						3						33
Streptomycin						2			2		2	3			ND
Kanamycin ^a							2		7						78
Florfenicol						1	7			1					ND
Chloramphenicol ^a					1	5	1		1	1					22
Tetracycline				1	1		2			1		4			56
Colistin			8			1									11
Sulphamethoxazole ^b									1					8	89
Trimethoprim ^b		1			2				6						67
<i>C. freundii</i> (n = 6)															
MIC [$\mu\text{g/mL}$]:	0.12	0.25	0.5	1	>2	4	8	16	>16	32	64	>128	256	>512	R (%)
Ampicilin ^a											1	5			100
Cefotaxime	1				5										83
Ceftazidime				1			1		4						83
Ciprofloxacin ^b	1			5											0
Nalidixic acid ^a						1						5			83
Gentamicin		1	1			2			2						33
Streptomycin					1	1			2	1			1		ND
Kanamycin ^b							3		3						50
Florfenicol						3	2		1						ND
Chloramphenicol ^a					1	2	1			1	1				33
Tetracycline				2						1	2	1			67
Colistin ^a			4		1	1									33
Sulphamethoxazole ^b							2		1					3	50

(Continued)

Table 2. (Continued)

Trimethoprim ^b		1						5												83
---------------------------	--	---	--	--	--	--	--	---	--	--	--	--	--	--	--	--	--	--	--	----

EUCAST (ECOFF values WT): AMP ≤8, CTX ≤0.25, CAZ ≤0.5 (≤1 *C. freundii*), CIP ≤0.064 (≤0.125 *K. pneumoniae*), NAL ≤16, GEN ≤2, STR ≤16, KAN ≤8, FFL ≤16, CHL ≤16, TET ≤8, COL ≤2, SMX ≤64, TMP ≤2 (≤8 *K. pneumoniae* and *C. freundii*).

^aBSAC and

^bCLSI clinical break points: CIP ≤1 *Enterobacteriaceae*, SMX Susceptible ≤256 *K. pneumoniae* and *C. freundii*; TMP ≤8 *K. pneumoniae* and *C. freundii*. ND, not determined due to lack of ECOFF or clinical breakpoint values available. CLSI: Performance Standards for Antimicrobial Susceptibility Testing, 27th ed. CLSI supplement M100. Wayne, PA: Clinical and Laboratory Standards Institute; 2017.

<https://doi.org/10.1371/journal.pone.0210686.t002>

frequent ESBL types identified not only in *E. coli* but also in *K. pneumoniae* and *C. freundii* isolates. *K. pneumoniae* has been described in low prevalence (average 1.5%) in wild gulls from different European countries [41–43], including wild migratory birds from Spain, which exhibited *bla*_{CTX-M-15} ESBL-producing *K. pneumoniae* [36]. Interestingly, both *bla*_{CTX-M-15} and *bla*_{SHV-12} are also currently the most predominant genes in human clinical specimens from community and health care-associated infections in Spain [44,45]. Thus, the human community could potentially be a source of ESBL environmental contamination, through water contaminated with human sewage from urban areas and hospital settings.

In this study, *bla*_{CMY-1} group was principally detected in *E. coli*, *K. pneumoniae*, *Proteus* and *Providencia* spp from avian wildlife, like hawks, owls and small forest birds. Although this is an unusual variant in Spain, the presence in the present study might be explained by those species feeding habits. Raptors are predators occupying the top of the food chain; therefore, they can acquire AMR from a wide variety of preys (mammals, birds, reptiles or scavenging livestock). Moreover, some of these raptors are migratory species, being exposed to different environmental habitats in their migratory movements. In consequence, the role of migratory raptors as disseminators of these AMR traits is a serious concern to be further investigated.

Regarding *bla*_{CMY-2}, it is the most common CMY type reported worldwide [46]. In this study, *bla*_{CMY-2} group was highly detected in *E. coli* and *K. pneumoniae* from hedgehogs and wild birds. Plasmid mediated genes can spread easily to other organisms. *C. freundii*, *Enterobacter* and *Serratia* spp in this study presented genes of the CMY-2 family. Since these types of AmpC genes are chromosomally encoded in some of these bacteria species, we cannot conclude the plasmidic nature of such enzymes. However, for epidemiological studies, it is important to report this type of resistance since these *Enterobacterales* can be involved in severe nosocomial infections and they all presented a MDR profile, except for *E. cloacae*.

Surprisingly, European hedgehogs represented an important reservoir of ESBL/AmpC-producing *E. coli* and other *Enterobacterales*, especially for *bla*_{CMY-2} (67%) and *bla*_{SHV-12} (25%) in this study. Our results are in agreement with previous studies conducted in Spain reporting low to moderate (1.3%-10%) prevalence of *bla*_{CMY-2} and *bla*_{SHV-12} *E. coli* variants in hedgehogs, deer and minks [22,47]. It is important to highlight that hedgehogs are in close contact with humans (home range including gardens), but also with livestock in the countryside, which could explain their acquisition of these AMR types.

Plasmid-mediated colistin resistance by *mcr-1* has been reported worldwide in *Enterobacterales* isolated from humans, livestock, companion animals, food and wildlife [48]. Colistin has been used in veterinary medicine during the last decades for the treatment of gastrointestinal infections in livestock, principally in pigs and poultry [49]. Consequently, livestock is considered the main reservoir of *mcr-1* selection and dissemination worldwide. Recent works disclosed the relationship among *mcr-1*-harbouring *E. coli* isolates recovered from the environment, pig production and human clinical isolates, demonstrating the rapidly evolving epidemiology of plasmid-mediated colistin-resistant *E. coli* strains worldwide and the importance of the One Health

approach [50,51]. In our study, some *Klebsiella* and *Providencia* spp isolates were phenotypically resistant to colistin, but no *mcr*-associated genes were detected in any of the examined isolates.

Information about carbapenem-resistant *Enterobacterales* is very scarce in wildlife and has only been reported in avian species [36,52]. In this study, we report the presence of *bla*_{OXA-48} in *E. coli* and *P. mirabilis* isolates from a European hedgehog and a Barn owl, respectively. The presence of *bla*_{OXA-48} in wild mammals and birds in Catalonia is highly indicative of the wide environmental pollution of this variant, commonly reported in hospitals in Spain [53].

To our knowledge, there are no reports in wildlife, especially in wild mammals, describing the presence of ESBL genes in such a variety of *Enterobacterales*, like *Klebsiella* spp, *Citrobacter* spp, *Serratia* spp, or *Enterobacter* spp in Spain. *C. freundii*, is considered an opportunistic pathogen, associated with nosocomial infections, especially in patients who have been hospitalized for a prolonged period of time. In the last years, this bacterium has been classified as an emerging health problem associated to urinary tract infections commonly diagnosed in health-care settings [54]. *E. cloacae* has been reported as important opportunistic and multi-resistant pathogen involved in outbreaks of hospital-acquired infections worldwide [55,56], including Spain [57]. ESBL- *S. marcescens* has also been classified as one of the top ten priority pathogens causing infections in intensive care units [58].

The high prevalence of CR *Enterobacterales* encountered in this study is really concerning, since wildlife is not directly exposed to any antimicrobial agent. Therefore, faecal contamination of water or soil with MDR bacteria and/or antimicrobial residues can lead to a selection pressure. Wastewaters from urban areas and hospitals have been identified as one of the major sources of AMR environmental contamination [2]. High prevalence of *bla*_{SHV-12} but also *bla*_{TEM-1} and *bla*_{CTX-M-1} alleles have been reported in aquatic environments (urban waters, natural or artificial water reservoirs, seawater or drinking water) in several countries worldwide, likely due to their relatively easy transmission to surface water through waste water treatment plant discharges [2,59]. In our study, wildlife in close contact with urban and farming areas of Catalonia carried a large variety of zoonotic/nosocomial bacteria genetically resistant to β -lactams-quinolones-tetracycline-sulfamethoxazole/trimethoprim-aminoglycosides with similar resistant genes to those found in livestock and clinical settings. However, further studies are needed to assess clonal relatedness among different cephalosporin and carbapenem resistant enterobacteria at the human-animal-environment interface.

Conclusions

This study describes for the first time a high prevalence of *Enterobacterales* harbouring a large variety of ESBL in addition to carbapenem resistant OXA-48 genes in wild mammals, remarkably in hedgehogs, and wild birds in Catalonia (northeast Spain). AmpC CMY-2 group and the ESBL genes *bla*_{SHV-12} and *bla*_{CTX-M-15} were the most frequent types identified in *E. coli*, *K. pneumoniae* and *C. freundii* isolates. These results support the concept that wildlife is a good sentinel of AMR environmental contamination and underline the importance of the One Health approach since wildlife can contribute indirectly to the dissemination of resistance genes into other natural environments.

Supporting information

S1 Table. Oligonucleotides used for the detection of ESBL/AmpC and colistin-resistance genes in this study. F, sense primer; R, antisense primer; bp, base pairs. (DOCX)

Acknowledgments

Our grateful thanks to the Torreferrussa WRC staff. A.C. was student of the Master's Degree in Zoonosis and One Health (UAB). The authors are also grateful to the Centres de Recerca de Catalunya (CERCA) Programme.

Author Contributions

Conceptualization: Laila Darwich.

Data curation: Laila Darwich, Anna Vidal, Chiara Seminati, Rafael A. Molina-López.

Formal analysis: Laila Darwich, Anna Vidal, Chiara Seminati, Andreu Albamonte, Alba Casado, Ferrán López, Rafael A. Molina-López.

Investigation: Laila Darwich, Anna Vidal, Chiara Seminati, Andreu Albamonte, Alba Casado, Ferrán López, Lourdes Migura-Garcia.

Methodology: Laila Darwich, Lourdes Migura-Garcia.

Project administration: Laila Darwich.

Software: Laila Darwich, Rafael A. Molina-López.

Supervision: Laila Darwich, Lourdes Migura-Garcia.

Validation: Laila Darwich, Rafael A. Molina-López, Lourdes Migura-Garcia.

Writing – original draft: Laila Darwich.

Writing – review & editing: Laila Darwich, Rafael A. Molina-López, Lourdes Migura-Garcia.

References

1. Pitout JD, Laupland KB. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. *Lancet Infect Dis*. 2008; 8(3):159–66. [https://doi.org/10.1016/S1473-3099\(08\)70041-0](https://doi.org/10.1016/S1473-3099(08)70041-0) PMID: 18291338
2. Liakopoulos A, Mevius D, Ceccarelli D. A Review of SHV Extended-Spectrum β -Lactamases: Neglected Yet Ubiquitous. *Front Microbiol*. 2016; 7:1374. 0.3389/fmicb.2016.01374.
3. Ambler RP. The structure of beta-lactamases. *Philos Trans R Soc Lond*. 1980; B289:321–331.
4. Ambler RP, Coulson AFW, Frère JM, Ghuyssen JM, Joris B, Forsman M, et al. A standard numbering scheme for the class A-lactamases. *Biochem J*. 1991; 276:269–272. <https://doi.org/10.1042/bj2760269> PMID: 2039479
5. Bush K, Jacoby GA. Updated functional classification of beta-lactamases. *Antimicrob Agents Chemother*. 2010; 54:969–76. <https://doi.org/10.1128/AAC.01009-09> PMID: 19995920
6. Tzouveleki LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in *Klebsiella pneumoniae* and other *Enterobacteriaceae*: An evolving crisis of global dimensions. *Clin Microbiol Rev*. 2012; 25:682–707 <https://doi.org/10.1128/CMR.05035-11> PMID: 23034326
7. Grundmann H, Glasner C, Albigier B, Aanensen DM, Tomlinson CT, Andrasević AT, et al. Occurrence of carbapenemase-producing *Klebsiella pneumoniae* and *Escherichia coli* in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study. *Lancet Infect Dis* 17:153–163. [https://doi.org/10.1016/S1473-3099\(16\)30257-2](https://doi.org/10.1016/S1473-3099(16)30257-2) PMID: 27866944
8. Jouini A, Vinué L, Slama KB, Sáenz Y, Klibi N, Hammami S, et al. Characterization of CTX-M and SHV extended-spectrum beta-lactamases and associated resistance genes in *Escherichia coli* strains of food samples in Tunisia. *J Antimicrob Chemother*. 2007; 60:1137–1141 <https://doi.org/10.1093/jac/dkm316> PMID: 17855726
9. Smet A, Martel A, Persoons D, Dewulf J, Heyndrickx M, Herman L, et al. Broad-spectrum β -lactamases among Enterobacteriaceae of animal origin: molecular aspects, mobility and impact on public health. *FEMS Microbiol Rev*. 2010; 34:295–316 <https://doi.org/10.1111/j.1574-6976.2009.00198.x> PMID: 20030731

10. Wieler LH, Ewers C, Guenther S, Walther B, Lübke-Becker A. Methicillin-resistant staphylococci (MRS) and extended spectrum-beta-lactamases (ESBL)-producing Enterobacteriaceae in companion animals: nosocomial infections as one reason for the rising prevalence of these potential zoonotic pathogens in clinical samples. *Int J Med Microbiol*. 2011; 301:635–641 <https://doi.org/10.1016/j.ijmm.2011.09.009> PMID: 22000738
11. Dierikx C, van der Goot J, Fabri T, van Essen-Zandbergen A, Smith H, Mevius D. Extended-spectrum- β -lactamase- and AmpC- β -lactamase-producing *Escherichia coli* in Dutch broilers and broiler farmers. *J Antimicrob Chemother*. 2013; 68:60–67 <https://doi.org/10.1093/jac/dks349> PMID: 22949623
12. Sallem RB, Gharsa H, Slama KB, Rojo-Bezares B, Estepa V, Porres-Osante N, et al. First detection of CTX-M-1, CMY-2, and QnrB19 resistance mechanisms in fecal *Escherichia coli* isolates from healthy pets in Tunisia. *Vector Borne Zoonotic Dis*. 2013; 13:98–102 <https://doi.org/10.1089/vbz.2012.1047> PMID: 23289399
13. Dorado-García A, Smid JH, van Pelt W, Bonten MJM, Fluit AC, van den Bunt G, et al. Molecular relatedness of ESBL/AmpC-producing *Escherichia coli* from humans, animals, food and the environment: a pooled analysis. *J Antimicrob Chemother*. 2018; 73(2):339–347. <https://doi.org/10.1093/jac/dkx397> PMID: 29165596
14. Huijbers PM, Blaak H, de Jong MC, Graat EA, Vandenbroucke-Grauls CM, de Roda Husman AM. Role of the Environment in the Transmission of Antimicrobial Resistance to Humans: A Review. *Environ Sci Technol*. 2015; 49(20):11993–2004 <https://doi.org/10.1021/acs.est.5b02566> PMID: 26355462
15. Alcalá L, Alonso CA, Simón C, González-Esteban C, Orós J, Rezusta A, et al. Wild Birds, Frequent Carriers of Extended-Spectrum β -Lactamase (ESBL) Producing *Escherichia coli* of CTX-M and SHV-12 Types. *Microb Ecol*. 2016; 72(4):861–869. <https://doi.org/10.1007/s00248-015-0718-0> PMID: 26687342
16. Hasan B, Laurell K, Rakib MM, Ahlstedt E, Hernandez J, Caceres M, et al. Fecal Carriage of Extended-Spectrum β -Lactamases in Healthy Humans, Poultry, and Wild Birds in León, Nicaragua—A Shared Pool of bla(CTX-M) Genes and Possible Interspecies Clonal Spread of Extended-Spectrum β -Lactamases-Producing *Escherichia coli*. *Microb Drug Resist*. 2016; 22(8):682–687. Epub 2016 Mar 23. <https://doi.org/10.1089/mdr.2015.0323> PMID: 27007258.
17. Parker D, Sniatynski MK, Mandrusiak D, Rubin JE. Extended-spectrum β -lactamase producing *Escherichia coli* isolated from wild birds in Saskatoon, Canada. *Lett Appl Microbiol*. 2016; 63(1):11–5. <https://doi.org/10.1111/lam.12589> PMID: 27214496
18. Atterby C, Börjesson S, Ny S, Järhult JD, Byfors S, Bonnedahl J. ESBL-producing *Escherichia coli* in Swedish gulls—A case of environmental pollution from humans? *PLoS One*. 2017; 12(12):e0190380. <https://doi.org/10.1371/journal.pone.0190380> PMID: 29284053
19. Mohsin M, Raza S, Schaufler K, Roschanski N, Sarwar F, Semmler T, et al. High Prevalence of CTX-M-15-Type ESBL-Producing *E. coli* from Migratory Avian Species in Pakistan. *Front Microbiol*. 2017; 8:2476. <https://doi.org/10.3389/fmicb.2017.02476> PMID: 29312186
20. Ben Yahia H, Ben Sallem R, Tayh G, Klibi N, Ben Amor I, Gharsa H, et al. Detection of CTX-M-15 harboring *Escherichia coli* isolated from wild birds in Tunisia. *BMC Microbiol*. 2018; 18(1):26. <https://doi.org/10.1186/s12866-018-1163-2> PMID: 29609544
21. Raza S, Mohsin M, Madni WA, Sarwar F, Saqib M, Aslam B. First Report of bla(CTX-M-15)-Type ESBL-Producing *Klebsiella pneumoniae* in Wild Migratory Birds in Pakistan. *Ecohealth*. 2017; 14(1):182–186. <https://doi.org/10.1007/s10393-016-1204-y> PMID: 28078492
22. Alonso CA, Alcalá L, Simón C, Torres C. Novel sequence types of extended-spectrum and acquired AmpC beta-lactamase producing *Escherichia coli* and *Escherichia* clade V isolated from wild mammals. *FEMS Microbiol Ecol*. 2017; 93(8). <https://doi.org/10.1093/femsec/fix097> PMID: 28873943
23. Cantón R, Loza E, Aznar J, Castillo FJ, Cercenado E, Fraile-Ribot PA, et al; SMART-Spain Working Group. Monitoring the antimicrobial susceptibility of Gram-negative organisms involved in intraabdominal and urinary tract infections recovered during the SMART study (Spain, 2016 and 2017). *Rev Esp Quimioter*. 2019; 32(2):145–155 PMID: 30761824
24. Spanish. R.D.1201/2005 of the Ministry of Presidency of Spain (10th October 2005). BOE 21st October 2005. Available: www.boe.es/boe/dias/2005/10/21/pdfs/A34367-34391.pdf. Accessed 2018 Dec 27.
25. Miro E, Navarro F, Mirelis B, et al. Prevalence of clinical isolates of *Escherichia coli* producing inhibitor-resistant β -lactamases at a University Hospital in Barcelona, Spain, over a 3-year period. *Antimicrob Agents Chemother*. 2002; 46: 3991–4. <https://doi.org/10.1128/AAC.46.12.3991-3994.2002> PMID: 12435708
26. Olesen I, Hasman H, Aarestrup FM. Prevalence of β -lactamases among ampicillin resistant *Escherichia coli* and *Salmonella* isolated from food animals in Denmark. *Microb Drug Resist*. 2004; 10: 334–40. <https://doi.org/10.1089/mdr.2004.10.334> PMID: 15650379

27. Arlet G, Rouveau M, Philippon A. Substitution of alanine for aspartate at position 179 in the SHV-6 extended-spectrum β -lactamase. *FEMS Microbiol. Lett.* 1997; 152:163–67. [https://doi.org/10.1016/s0378-1097\(97\)00196-1](https://doi.org/10.1016/s0378-1097(97)00196-1) PMID: 9228783
28. Kim J, Kwon Y, Pai H, Kim JW, Cho DT. Survey of *Klebsiella pneumoniae* strains producing extended-spectrum beta-lactamases: prevalence of SHV-12 and SHV-2a in Korea. *J Clin. Microbiol.* 1998; 36:1446–49. PMID: 9574728
29. Hasman H, Mevius D, Veldman K, Olesen I, Aarestrup FM. 2005. b-Lactamases among extended-spectrum b-lactamase (ESBL)-resistant *Salmonella* from poultry, poultry products and human patients in The Netherlands. *J Antimicrob Chemother.* 2005; 56:115–121. <https://doi.org/10.1093/jac/dki190> PMID: 15941775
30. Poirel L, Walsh TR, Cuvillier V, Nordmann P. Multiplex PCR for detection of acquired carbapenemase genes. *Diagn Microbiol Infect Dis.* 2011; 70(1):119–23. <https://doi.org/10.1016/j.diagmicrobio.2010.12.002> PMID: 21398074
31. Rebelo AR, Bortolaia V, Kjeldgaard JS, Pedersen SK, Leekitcharoenphon P, et al. Multiplex PCR for detection of plasmid-mediated colistin resistance determinants, mcr-1, mcr-2, mcr-3, mcr-4 and mcr-5 for surveillance purposes *Euro Surveill.* 2018; 23: 17–00672.
32. Guenther S, Ewers C, Wieler LH. Extended-Spectrum Beta-Lactamases Producing *E. coli* in Wildlife, yet another Form of Environmental Pollution? *Front Microbiol.* 2011; 2:246 <https://doi.org/10.3389/fmicb.2011.00246> PMID: 22203818
33. Simões RR, Poirel L, Da Costa PM, Nordmann P. Seagulls and beaches as reservoirs for multidrug-resistant *Escherichia coli*. *Emerg Infect Dis.* 2010; 16(1):110–2. <https://doi.org/10.3201/eid1601.090896> PMID: 20031053
34. Vergara A, Pitart C, Montalvo T, Roca I, Sabaté S, Hurtado JC, et al. Prevalence of Extended-Spectrum- β -Lactamase- and/or Carbapenemase-Producing *Escherichia coli* Isolated from Yellow-Legged Gulls from Barcelona, Spain. *Antimicrob Agents Chemother.* 2017 Jan 24; 61(2). pii: e02071–16. <https://doi.org/10.1128/AAC.02071-16> PMID: 27919890
35. Alonso CA, Michael GB, Li J, Somalo S, Simón C, Wang Y, et al. Analysis of blaSHV-12-carrying *Escherichia coli* clones and plasmids from human, animal and food sources. *J Antimicrob Chemother.* 2017; 72(6):1589–1596. <https://doi.org/10.1093/jac/dkx024> PMID: 28333184
36. Oteo J, Mencia A, Bautista V, Pastor N, Lara N, González-González F, et al. Colonization with Enterobacteriaceae-Producing ESBLs, AmpCs, and OXA-48 in Wild Avian Species, Spain 2015–2016. *Microb Drug Resist.* 2018; 24:932–938 <https://doi.org/10.1089/mdr.2018.0004> PMID: 29782210
37. Costa D, Poeta P, Sáenz Y, Vinué L, Rojo-Bezares B, Jouini A, et al. Detection of *Escherichia coli* harbouring extended-spectrum beta-lactamases of the CTX-M, TEM and SHV classes in faecal samples of wild animals in Portugal. *J Antimicrob Chemother.* 2006; 58(6):1311–2. <https://doi.org/10.1093/jac/dkl415> PMID: 17023496
38. Veldman K, van Tulden P, Kant A, Testerink J, Mevius D. Characteristics of cefotaxime-resistant *Escherichia coli* from wild birds in the Netherlands. *Appl Environ Microbiol.* 2013; 79(24):7556–61. <https://doi.org/10.1128/AEM.01880-13> PMID: 24038683
39. Literak I, Dolejska M, Janoszowska D, Hrusakova J, Meissner W, Rzycka H, et al. Antibiotic-resistant *Escherichia coli* bacteria, including strains with genes encoding the extended-spectrum beta-lactamase and QnrS, in waterbirds on the Baltic Sea Coast of Poland. *Appl Environ Microbiol.* 2010; 76(24):8126–34. <https://doi.org/10.1128/AEM.01446-10> PMID: 20952638
40. Dolejská M, Bierosová B, Kohoutová L, Literák I, Cízek A. Antibiotic-resistant *Salmonella* and *Escherichia coli* isolates with integrons and extended-spectrum beta-lactamases in surface water and sympatric black-headed gulls. *J Appl Microbiol.* 2009; 106(6):1941–50. <https://doi.org/10.1111/j.1365-2672.2009.04155.x> PMID: 19245407
41. Bonnedahl J, Stedt J, Waldenström J, Svensson L, Drobni M, Olsen B. Comparison of Extended-Spectrum β -Lactamase (ESBL) CTX-M Genotypes in Franklin Gulls from Canada and Chile. *PLoS One.* 2015; 10(10):e0141315 <https://doi.org/10.1371/journal.pone.0141315> PMID: 26496629
42. Stedt J, Bonnedahl J, Hernandez J, Waldenström J, McMahon BJ, Tolf C, et al. Carriage of CTX-M type extended spectrum β -lactamases (ESBLs) in gulls across Europe. *Acta Vet Scand.* 2015; 57:74. <https://doi.org/10.1186/s13028-015-0166-3> PMID: 26526188
43. Bonnedahl J, Hernandez J, Stedt J, Waldenström J, Olsen B, Drobni M. Extended-spectrum β -lactamases in *Escherichia coli* and *Klebsiella pneumoniae* in Gulls, Alaska, USA. *Emerg Infect Dis.* 2014; 20(5):897–9. <https://doi.org/10.3201/eid2005.130325> PMID: 24750592
44. Díaz MA, Hernández-Bello JR, Rodríguez-Baño J, Martínez-Martínez L, Calvo J, Blanco J, et al. Spanish Group for Nosocomial Infections (GEIH). Diversity of *Escherichia coli* strains producing extended-spectrum beta-lactamases in Spain: second nationwide study. *J Clin Microbiol.* 2010; 48(8):2840–5. <https://doi.org/10.1128/JCM.02147-09>

45. Merino I, Shaw E, Horcajada JP, Cercenado E, Mirelis B, Pallarés MA, et al. ITUBRAS-GEIH-SEIMC Group. CTX-M-15-H30Rx-ST131 subclone is one of the main causes of healthcare-associated ESBL-producing *Escherichia coli* bacteraemia of urinary origin in Spain. *J Antimicrob Chemother.* 2016; 71(8):2125–30. <https://doi.org/10.1093/jac/dkw133> PMID: 27494832
46. Jacoby GA. AmpC beta-lactamases. *Clin Microbiol Rev.* 2009; 22(1):161–82 <https://doi.org/10.1128/CMR.00036-08> PMID: 19136439
47. Cristóvão F, Alonso CA, Igrejas G, Sousa M, Silva V, Pereira JE, et al. Clonal diversity of extended-spectrum beta-lactamase producing *Escherichia coli* isolates in fecal samples of wild animals. *FEMS Microbiol Lett.* 2017; 364(5).
48. Skov RL, Monnet DL. Plasmid-mediated colistin resistance (*mcr-1* gene): three months later, the story unfolds. *Euro Surveill.* 2016; 21:30155 <https://doi.org/10.2807/1560-7917.ES.2016.21.9.30155> PMID: 26967914
49. EMA. Updated Advice on the Use of Colistin Products in Animals within the European Union: Development of Resistance and Possible Impact on Human and Animal Health. 2016. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2016/07/WC500211081.pdf.
50. Guenther S, Falgenhauer L, Semmler T, Imirzalioglu C, Chakraborty T, Roesler U, et al. Environmental emission of multiresistant *Escherichia coli* carrying the colistin resistance gene *mcr-1* from German swine farms. *J Antimicrob Chemother.* 2017; 72(5):1289–1292. <https://doi.org/10.1093/jac/dkw585> PMID: 28122910
51. García-Meniño I, García V, Mora A, Díaz-Jiménez D, Flament-Simon SC, Alonso, et al. J. Swine Enteric Colibacillosis in Spain: Pathogenic Potential of *mcr-1* ST10 and ST131 *E. coli* Isolates. *Front Microbiol.* 2018; 9:2659 <https://doi.org/10.3389/fmicb.2018.02659> PMID: 30455680
52. Fischer J, Schmogger S, Jahn S, Helmuth R, Guerra B. NDM-1 carbapenemase-producing *Salmonella enterica* subsp. *enterica* serovar Corvallis isolated from a wild bird in Germany. *J Antimicrob Chemother.* 2013; 68(12):2954–6. <https://doi.org/10.1093/jac/dkt260> PMID: 23818284
53. Aracil-García B, Oteo-Iglesias J, Cuevas-Lobato Ó, Lara-Fuella N, Pérez-Grajera I, Fernández-Romero S, et al. Spanish Group European Antimicrobial Resistance Surveillance network (EARS-Net). Rapid increase in resistance to third generation cephalosporins, imipenem and co-resistance in *Klebsiella pneumoniae* from isolated from 7,140 blood-cultures (2010–2014) using EARS-Net data in Spain. *Enferm Infecc Microbiol Clin.* 2017; 35(8):480–486 <https://doi.org/10.1016/j.imec.2016.06.007> PMID: 27469416
54. Ranjan KP, Ranjan N. *Citrobacter*: An emerging health care associated urinary pathogen. *Urology Annals.* 2013; 5(4):313–314. PMID: 24311922
55. Davin-Regli A, Pagès JM. *Enterobacter aerogenes* and *Enterobacter cloacae*; versatile bacterial pathogens confronting antibiotic treatment. *Frontiers Microbiol.* 2015; 6:392.
56. Annavajhala MK, Gomez-Simmonds A, Uhlemann AC. Multidrug-Resistant *Enterobacter cloacae* Complex Emerging as a Global, Diversifying Threat. *Front Microbiol.* 2019; 10:44. Review <https://doi.org/10.3389/fmicb.2019.00044> PMID: 30766518
57. Fernández J, Montero I, Martínez Ó, Fleites A, Poirel L, Nordmann P, Rodicio MR. Dissemination of multiresistant *Enterobacter cloacae* isolates producing OXA-48 and CTX-M-15 in a Spanish hospital. *Int J Antimicrob Agents.* 2015; 46(4):469–74. <https://doi.org/10.1016/j.ijantimicag.2015.07.003> PMID: 26307466
58. Dessì A, Puddu M, Testa M, Marcialis MA, Pintus MC, Fanos V. *Serratia marcescens* infections and outbreaks in neonatal intensive care units. *J Chemother.* 2009 Nov; 21(5):493–9. <https://doi.org/10.1179/joc.2009.21.5.493> PMID: 19933039
59. Rashid M, Rakib MM, Hasan B. Antimicrobial-resistant and ESBL-producing *Escherichia coli* in different ecological niches in Bangladesh. *Infect Ecol Epidemiol.* 2015; 5:26712. <https://doi.org/10.3402/iee.v5.26712> PMID: 26193990